| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2024 | 188 | 4.640 |
Why?
|
| Kidney Tubules | 12 | 2024 | 38 | 4.320 |
Why?
|
| MicroRNAs | 11 | 2024 | 501 | 3.900 |
Why?
|
| Epithelial Cells | 20 | 2024 | 426 | 3.420 |
Why?
|
| Exosomes | 8 | 2024 | 124 | 3.190 |
Why?
|
| HIV-1 | 21 | 2024 | 747 | 3.100 |
Why?
|
| Kidney Tubules, Proximal | 9 | 2024 | 34 | 2.750 |
Why?
|
| Diabetic Nephropathies | 9 | 2024 | 74 | 2.730 |
Why?
|
| Reperfusion Injury | 5 | 2023 | 57 | 2.360 |
Why?
|
| RNA, Messenger | 17 | 2021 | 1265 | 2.320 |
Why?
|
| Macrophages | 7 | 2024 | 515 | 2.220 |
Why?
|
| Kidney Diseases | 7 | 2020 | 170 | 2.180 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 9 | 2024 | 16 | 1.980 |
Why?
|
| Inflammation | 13 | 2023 | 729 | 1.880 |
Why?
|
| Cytidine Deaminase | 12 | 2014 | 36 | 1.870 |
Why?
|
| Fibrosis | 13 | 2024 | 166 | 1.860 |
Why?
|
| Kidney Failure, Chronic | 6 | 2020 | 239 | 1.820 |
Why?
|
| Nephritis, Interstitial | 5 | 2018 | 7 | 1.770 |
Why?
|
| Angiotensin II | 6 | 2024 | 103 | 1.720 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2024 | 85 | 1.700 |
Why?
|
| Mice | 28 | 2024 | 6490 | 1.260 |
Why?
|
| Podocytes | 5 | 2024 | 37 | 1.240 |
Why?
|
| Kidney | 11 | 2023 | 363 | 1.220 |
Why?
|
| Biphenyl Compounds | 4 | 2011 | 52 | 1.210 |
Why?
|
| Tetrazoles | 4 | 2011 | 45 | 1.190 |
Why?
|
| Humans | 77 | 2024 | 42163 | 1.190 |
Why?
|
| Cells, Cultured | 18 | 2022 | 1617 | 1.180 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 1804 | 1.160 |
Why?
|
| Male | 43 | 2024 | 22779 | 1.130 |
Why?
|
| Signal Transduction | 9 | 2024 | 2111 | 1.120 |
Why?
|
| Renal Dialysis | 4 | 2022 | 124 | 1.100 |
Why?
|
| Animals | 41 | 2024 | 16695 | 1.100 |
Why?
|
| Calcinosis | 2 | 2022 | 61 | 1.100 |
Why?
|
| Kidney Glomerulus | 3 | 2021 | 85 | 1.090 |
Why?
|
| Cell Line | 18 | 2024 | 1416 | 1.080 |
Why?
|
| Uric Acid | 2 | 2020 | 29 | 1.060 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2019 | 97 | 1.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2011 | 37 | 1.030 |
Why?
|
| Immediate-Early Proteins | 5 | 2007 | 50 | 1.010 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2021 | 126 | 0.990 |
Why?
|
| Carrier Proteins | 4 | 2018 | 318 | 0.980 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2007 | 100 | 0.980 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 1554 | 0.960 |
Why?
|
| Nephroblastoma Overexpressed Protein | 2 | 2017 | 3 | 0.940 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 5 | 2015 | 18 | 0.930 |
Why?
|
| Receptors, LDL | 3 | 2015 | 40 | 0.930 |
Why?
|
| Membrane Proteins | 6 | 2024 | 548 | 0.910 |
Why?
|
| Virus Assembly | 8 | 2015 | 44 | 0.900 |
Why?
|
| Macrophage Activation | 3 | 2021 | 59 | 0.900 |
Why?
|
| Telomere | 2 | 2024 | 59 | 0.890 |
Why?
|
| Lectins, C-Type | 2 | 2021 | 37 | 0.850 |
Why?
|
| Diaphragm | 2 | 2022 | 11 | 0.840 |
Why?
|
| DNA, Complementary | 1 | 2024 | 195 | 0.840 |
Why?
|
| Viral Envelope Proteins | 2 | 2015 | 90 | 0.830 |
Why?
|
| Hexokinase | 1 | 2023 | 10 | 0.820 |
Why?
|
| Lysine | 2 | 2016 | 120 | 0.810 |
Why?
|
| Disease Progression | 5 | 2024 | 661 | 0.770 |
Why?
|
| Mice, Knockout | 9 | 2024 | 1010 | 0.770 |
Why?
|
| Virion | 4 | 2014 | 73 | 0.760 |
Why?
|
| Virus Replication | 8 | 2024 | 318 | 0.760 |
Why?
|
| Cytosine Deaminase | 3 | 2014 | 7 | 0.750 |
Why?
|
| Actins | 10 | 2016 | 162 | 0.750 |
Why?
|
| Mitochondria | 2 | 2018 | 516 | 0.750 |
Why?
|
| Transcription Factor RelA | 2 | 2021 | 41 | 0.730 |
Why?
|
| Interleukin-1beta | 3 | 2018 | 74 | 0.730 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 33 | 0.730 |
Why?
|
| China | 8 | 2024 | 233 | 0.720 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2021 | 15 | 0.720 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.680 |
Why?
|
| Glomerular Filtration Rate | 3 | 2016 | 144 | 0.680 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 72 | 0.660 |
Why?
|
| Transfection | 9 | 2016 | 526 | 0.660 |
Why?
|
| NF-kappa B | 4 | 2021 | 355 | 0.660 |
Why?
|
| Autophagy | 1 | 2021 | 136 | 0.650 |
Why?
|
| Connective Tissue Growth Factor | 6 | 2012 | 18 | 0.650 |
Why?
|
| Muscle Weakness | 1 | 2019 | 7 | 0.650 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 158 | 0.640 |
Why?
|
| Mutation | 4 | 2024 | 1169 | 0.640 |
Why?
|
| Gene Products, vif | 5 | 2006 | 6 | 0.630 |
Why?
|
| Middle Aged | 18 | 2024 | 11819 | 0.630 |
Why?
|
| Albuminuria | 3 | 2015 | 78 | 0.620 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2019 | 13 | 0.600 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2012 | 649 | 0.590 |
Why?
|
| Regeneration | 1 | 2018 | 29 | 0.590 |
Why?
|
| Down-Regulation | 6 | 2021 | 452 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 233 | 0.590 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 164 | 0.570 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2018 | 4 | 0.560 |
Why?
|
| Collagen | 1 | 2019 | 178 | 0.560 |
Why?
|
| Female | 24 | 2024 | 24018 | 0.560 |
Why?
|
| Thioredoxins | 1 | 2018 | 36 | 0.550 |
Why?
|
| Nephrectomy | 3 | 2020 | 29 | 0.550 |
Why?
|
| Ureteral Obstruction | 4 | 2021 | 16 | 0.550 |
Why?
|
| Rats | 10 | 2021 | 3701 | 0.550 |
Why?
|
| Mesangial Cells | 1 | 2017 | 9 | 0.550 |
Why?
|
| Aorta | 2 | 2016 | 197 | 0.550 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 55 | 0.540 |
Why?
|
| Homeostasis | 1 | 2018 | 193 | 0.540 |
Why?
|
| Ubiquitin | 2 | 2016 | 80 | 0.530 |
Why?
|
| Adult | 16 | 2021 | 13458 | 0.520 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 95 | 0.510 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2016 | 3 | 0.510 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 129 | 0.510 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 10 | 0.490 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2015 | 2 | 0.490 |
Why?
|
| Gene Expression | 6 | 2012 | 692 | 0.490 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 146 | 0.490 |
Why?
|
| Cost of Illness | 1 | 2016 | 95 | 0.480 |
Why?
|
| Health Care Costs | 1 | 2016 | 89 | 0.480 |
Why?
|
| Population Surveillance | 2 | 2016 | 245 | 0.470 |
Why?
|
| Apolipoproteins E | 2 | 2013 | 137 | 0.470 |
Why?
|
| Insurance Coverage | 1 | 2016 | 108 | 0.460 |
Why?
|
| Endothelial Cells | 2 | 2016 | 324 | 0.460 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 518 | 0.460 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 184 | 0.460 |
Why?
|
| Serum Albumin | 1 | 2015 | 58 | 0.450 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 228 | 0.450 |
Why?
|
| Atherosclerosis | 2 | 2013 | 164 | 0.440 |
Why?
|
| Adhesins, Bacterial | 1 | 2014 | 20 | 0.440 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 1066 | 0.440 |
Why?
|
| Glucose | 1 | 2016 | 242 | 0.430 |
Why?
|
| Endopeptidases | 1 | 2014 | 63 | 0.430 |
Why?
|
| Nephritis | 3 | 2019 | 7 | 0.430 |
Why?
|
| Proteinuria | 4 | 2020 | 55 | 0.430 |
Why?
|
| Hyperuricemia | 1 | 2014 | 13 | 0.430 |
Why?
|
| Cell Membrane | 2 | 2014 | 400 | 0.430 |
Why?
|
| Aged | 12 | 2024 | 7982 | 0.420 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2013 | 3 | 0.420 |
Why?
|
| Vagina | 1 | 2014 | 89 | 0.420 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2013 | 5 | 0.420 |
Why?
|
| RNA Interference | 5 | 2021 | 246 | 0.420 |
Why?
|
| Foam Cells | 1 | 2013 | 16 | 0.420 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 29 | 0.410 |
Why?
|
| Monocytes | 2 | 2013 | 275 | 0.410 |
Why?
|
| Cordyceps | 1 | 2013 | 4 | 0.410 |
Why?
|
| Smad Proteins | 1 | 2013 | 12 | 0.410 |
Why?
|
| Aortic Diseases | 1 | 2013 | 34 | 0.410 |
Why?
|
| Risk Assessment | 1 | 2016 | 845 | 0.410 |
Why?
|
| Pyridones | 1 | 2013 | 50 | 0.400 |
Why?
|
| GB virus C | 1 | 2013 | 2 | 0.400 |
Why?
|
| Dexamethasone | 1 | 2013 | 55 | 0.390 |
Why?
|
| Base Sequence | 6 | 2021 | 997 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 147 | 0.380 |
Why?
|
| Fibronectins | 4 | 2017 | 69 | 0.380 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2013 | 142 | 0.380 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 436 | 0.380 |
Why?
|
| Lysosomes | 3 | 2020 | 88 | 0.370 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1266 | 0.370 |
Why?
|
| Prognosis | 4 | 2020 | 850 | 0.360 |
Why?
|
| Microscopy, Confocal | 4 | 2015 | 223 | 0.350 |
Why?
|
| Polyubiquitin | 1 | 2011 | 7 | 0.350 |
Why?
|
| Hemagglutinins | 1 | 2011 | 9 | 0.350 |
Why?
|
| Cullin Proteins | 3 | 2005 | 12 | 0.350 |
Why?
|
| Lipids | 1 | 2013 | 256 | 0.350 |
Why?
|
| Blotting, Western | 7 | 2015 | 884 | 0.350 |
Why?
|
| Mesoderm | 4 | 2007 | 73 | 0.350 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2021 | 1737 | 0.340 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 19 | 0.340 |
Why?
|
| Myocardium | 1 | 2013 | 251 | 0.340 |
Why?
|
| Rats, Wistar | 3 | 2019 | 282 | 0.330 |
Why?
|
| Heart Failure | 2 | 2024 | 298 | 0.330 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 475 | 0.320 |
Why?
|
| Plant Extracts | 1 | 2013 | 303 | 0.320 |
Why?
|
| Ubiquitination | 1 | 2010 | 60 | 0.320 |
Why?
|
| Heart | 1 | 2011 | 181 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 96 | 0.310 |
Why?
|
| Glycine | 2 | 2019 | 47 | 0.310 |
Why?
|
| Anemia | 2 | 2019 | 52 | 0.300 |
Why?
|
| Isoquinolines | 2 | 2019 | 50 | 0.300 |
Why?
|
| Hemoglobins | 2 | 2019 | 112 | 0.300 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 196 | 0.300 |
Why?
|
| DNA Primers | 4 | 2013 | 295 | 0.300 |
Why?
|
| Hyperkalemia | 3 | 2024 | 13 | 0.300 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 683 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 285 | 0.290 |
Why?
|
| Simian immunodeficiency virus | 2 | 2010 | 61 | 0.280 |
Why?
|
| Cell Communication | 2 | 2018 | 110 | 0.280 |
Why?
|
| Cell Transdifferentiation | 1 | 2007 | 8 | 0.280 |
Why?
|
| Vimentin | 2 | 2024 | 38 | 0.280 |
Why?
|
| HIV Infections | 6 | 2024 | 2535 | 0.270 |
Why?
|
| Proteins | 3 | 2004 | 383 | 0.260 |
Why?
|
| Gene Products, gag | 4 | 2004 | 11 | 0.260 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2803 | 0.250 |
Why?
|
| Prevalence | 3 | 2016 | 1597 | 0.250 |
Why?
|
| Ultrasonography | 3 | 2022 | 132 | 0.250 |
Why?
|
| Cytokines | 2 | 2021 | 661 | 0.250 |
Why?
|
| Random Allocation | 2 | 2021 | 145 | 0.240 |
Why?
|
| Cadherins | 4 | 2013 | 102 | 0.240 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 378 | 0.240 |
Why?
|
| Age Distribution | 2 | 2016 | 249 | 0.230 |
Why?
|
| Virus Release | 2 | 2015 | 8 | 0.220 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2017 | 95 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 90 | 0.220 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3077 | 0.220 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2024 | 9 | 0.220 |
Why?
|
| Risk Factors | 3 | 2020 | 3942 | 0.220 |
Why?
|
| Hela Cells | 3 | 2015 | 370 | 0.220 |
Why?
|
| DNA, Viral | 3 | 2024 | 323 | 0.220 |
Why?
|
| Leupeptins | 1 | 2004 | 12 | 0.220 |
Why?
|
| Advisory Committees | 1 | 2024 | 34 | 0.210 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 22 | 0.210 |
Why?
|
| Nucleoside Deaminases | 5 | 2007 | 7 | 0.210 |
Why?
|
| Hot Temperature | 2 | 2014 | 141 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 159 | 0.210 |
Why?
|
| Phosphorylation | 2 | 2019 | 973 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 2 | 2016 | 80 | 0.200 |
Why?
|
| Up-Regulation | 2 | 2017 | 534 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2005 | 189 | 0.200 |
Why?
|
| Apoptosis | 4 | 2024 | 1541 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1420 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 1054 | 0.200 |
Why?
|
| Hematinics | 2 | 2019 | 8 | 0.200 |
Why?
|
| Quercetin | 1 | 2023 | 46 | 0.190 |
Why?
|
| Protein Transport | 2 | 2014 | 295 | 0.190 |
Why?
|
| Transcriptional Activation | 1 | 2023 | 173 | 0.190 |
Why?
|
| Area Under Curve | 2 | 2014 | 95 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 36 | 0.190 |
Why?
|
| ROC Curve | 2 | 2014 | 157 | 0.190 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2013 | 58 | 0.190 |
Why?
|
| Aortic Valve | 1 | 2022 | 38 | 0.180 |
Why?
|
| Young Adult | 4 | 2021 | 4936 | 0.180 |
Why?
|
| Ergocalciferols | 1 | 2021 | 6 | 0.180 |
Why?
|
| Chemokine CCL21 | 1 | 2021 | 14 | 0.180 |
Why?
|
| Phosphorus | 1 | 2022 | 65 | 0.180 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 50 | 0.180 |
Why?
|
| Caspase 8 | 1 | 2021 | 32 | 0.180 |
Why?
|
| Necrosis | 1 | 2021 | 54 | 0.180 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 27 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2485 | 0.180 |
Why?
|
| Chemokines | 1 | 2022 | 97 | 0.180 |
Why?
|
| Tight Junctions | 1 | 2021 | 27 | 0.180 |
Why?
|
| Rats, Inbred SHR | 2 | 2011 | 30 | 0.180 |
Why?
|
| 3' Untranslated Regions | 1 | 2021 | 81 | 0.180 |
Why?
|
| Cyclin B1 | 1 | 2021 | 18 | 0.180 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 20 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 201 | 0.180 |
Why?
|
| G2 Phase | 1 | 2021 | 29 | 0.170 |
Why?
|
| Cell Division | 2 | 2021 | 314 | 0.170 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 76 | 0.170 |
Why?
|
| Muscle, Smooth | 3 | 2012 | 59 | 0.170 |
Why?
|
| Ischemia | 1 | 2021 | 45 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 206 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 387 | 0.170 |
Why?
|
| Repressor Proteins | 5 | 2007 | 267 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 64 | 0.170 |
Why?
|
| Caspase 3 | 1 | 2021 | 226 | 0.170 |
Why?
|
| Tissue Distribution | 1 | 2021 | 230 | 0.170 |
Why?
|
| Cell Death | 1 | 2021 | 277 | 0.170 |
Why?
|
| Erythrocytes | 1 | 2021 | 126 | 0.170 |
Why?
|
| Albumins | 1 | 2020 | 32 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 152 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 88 | 0.160 |
Why?
|
| Hiccup | 1 | 2019 | 1 | 0.160 |
Why?
|
| Total Lung Capacity | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cholesterol | 3 | 2019 | 230 | 0.160 |
Why?
|
| Dyspnea | 1 | 2019 | 23 | 0.160 |
Why?
|
| DNA Damage | 1 | 2022 | 358 | 0.160 |
Why?
|
| Epoetin Alfa | 1 | 2019 | 2 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 602 | 0.160 |
Why?
|
| Plasmids | 2 | 2013 | 247 | 0.160 |
Why?
|
| Peptides | 2 | 2021 | 357 | 0.160 |
Why?
|
| Hypertension | 2 | 2024 | 823 | 0.160 |
Why?
|
| Cyclohexylamines | 1 | 2019 | 12 | 0.150 |
Why?
|
| Smad2 Protein | 1 | 2019 | 11 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1112 | 0.150 |
Why?
|
| Fatigue | 1 | 2019 | 97 | 0.150 |
Why?
|
| Adenine | 1 | 2019 | 48 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2021 | 199 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 427 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 57 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2018 | 59 | 0.150 |
Why?
|
| Benzamides | 1 | 2019 | 78 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 686 | 0.140 |
Why?
|
| Biological Transport | 1 | 2018 | 201 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 30 | 0.140 |
Why?
|
| Virus Internalization | 1 | 2018 | 36 | 0.140 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 39 | 0.140 |
Why?
|
| Organophosphorus Compounds | 1 | 2018 | 37 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 928 | 0.140 |
Why?
|
| Piperidines | 1 | 2018 | 80 | 0.140 |
Why?
|
| Serum Albumin, Bovine | 1 | 2018 | 49 | 0.140 |
Why?
|
| Enzyme Activation | 2 | 2016 | 462 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2017 | 35 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 51 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 708 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2018 | 154 | 0.130 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2016 | 11 | 0.130 |
Why?
|
| Phenotype | 2 | 2016 | 774 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 126 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1051 | 0.120 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2009 | 52 | 0.120 |
Why?
|
| Cause of Death | 1 | 2016 | 183 | 0.120 |
Why?
|
| Lentiviruses, Primate | 2 | 2005 | 2 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2013 | 105 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 136 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 2 | 2005 | 8 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2015 | 16 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 522 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 1729 | 0.120 |
Why?
|
| RNA, Viral | 2 | 2014 | 317 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2015 | 35 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2016 | 206 | 0.110 |
Why?
|
| Hypertrophy | 2 | 2005 | 34 | 0.110 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 62 | 0.110 |
Why?
|
| Enzyme Stability | 1 | 2014 | 35 | 0.110 |
Why?
|
| Streptococcus | 1 | 2014 | 18 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2006 | 348 | 0.110 |
Why?
|
| Antioxidants | 1 | 2018 | 439 | 0.110 |
Why?
|
| Point Mutation | 1 | 2014 | 98 | 0.110 |
Why?
|
| Endosomes | 1 | 2014 | 34 | 0.110 |
Why?
|
| Cell Movement | 1 | 2018 | 640 | 0.110 |
Why?
|
| Ultracentrifugation | 1 | 2013 | 14 | 0.110 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2013 | 35 | 0.110 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2013 | 29 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 11 | 0.100 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 28 | 0.100 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2013 | 13 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 140 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2014 | 224 | 0.100 |
Why?
|
| Registries | 1 | 2016 | 431 | 0.100 |
Why?
|
| S Phase | 1 | 2013 | 37 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 151 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 254 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 82 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 744 | 0.100 |
Why?
|
| Age Factors | 1 | 2016 | 1139 | 0.100 |
Why?
|
| Serum Amyloid A Protein | 1 | 2013 | 14 | 0.100 |
Why?
|
| Endothelium | 1 | 2013 | 28 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 59 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 108 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 438 | 0.100 |
Why?
|
| Glycosylation | 1 | 2013 | 111 | 0.100 |
Why?
|
| Triglycerides | 1 | 2013 | 146 | 0.100 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 3 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 200 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2014 | 587 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 638 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 401 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2006 | 301 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2012 | 64 | 0.090 |
Why?
|
| Biopsy | 1 | 2012 | 176 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 201 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 326 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2013 | 237 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 1559 | 0.090 |
Why?
|
| Actinin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Sialoglycoproteins | 1 | 2011 | 14 | 0.090 |
Why?
|
| Jurkat Cells | 3 | 2009 | 84 | 0.090 |
Why?
|
| Desmin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 239 | 0.090 |
Why?
|
| Rats, Inbred WKY | 1 | 2011 | 16 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 658 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 764 | 0.090 |
Why?
|
| Viral Load | 1 | 2013 | 344 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 72 | 0.090 |
Why?
|
| Creatinine | 1 | 2011 | 102 | 0.090 |
Why?
|
| Logistic Models | 1 | 2014 | 1001 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 184 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2014 | 359 | 0.090 |
Why?
|
| Time Factors | 2 | 2016 | 1848 | 0.090 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 209 | 0.080 |
Why?
|
| Prostate | 1 | 2011 | 152 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 41 | 0.080 |
Why?
|
| Echocardiography | 1 | 2011 | 167 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 114 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 293 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1221 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 111 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2013 | 633 | 0.080 |
Why?
|
| Recombination, Genetic | 2 | 2007 | 96 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 733 | 0.080 |
Why?
|
| Cisplatin | 2 | 2022 | 91 | 0.080 |
Why?
|
| Arrestins | 1 | 2009 | 28 | 0.080 |
Why?
|
| COS Cells | 3 | 2004 | 67 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2019 | 305 | 0.070 |
Why?
|
| Morphine | 1 | 2009 | 68 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1058 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 124 | 0.070 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Signal Recognition Particle | 1 | 2007 | 6 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 531 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 96 | 0.070 |
Why?
|
| Integrases | 1 | 2007 | 29 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 502 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2011 | 662 | 0.070 |
Why?
|
| HIV Integrase | 1 | 2007 | 22 | 0.070 |
Why?
|
| Virus Integration | 1 | 2007 | 65 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 40 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 25 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 2011 | 1188 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 207 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 5950 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2002 | 165 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2003 | 411 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2004 | 12 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 168 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 30 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2008 | 92 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 53 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 44 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 78 | 0.050 |
Why?
|
| Mitogens | 1 | 2003 | 10 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 69 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 64 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 158 | 0.050 |
Why?
|
| Cell Separation | 1 | 2003 | 94 | 0.050 |
Why?
|
| Endocytosis | 1 | 2024 | 117 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 115 | 0.050 |
Why?
|
| Sindbis Virus | 1 | 2002 | 14 | 0.050 |
Why?
|
| Gene Products, env | 1 | 2002 | 23 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 57 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2022 | 36 | 0.050 |
Why?
|
| Aquaporin 2 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 235 | 0.040 |
Why?
|
| Sulfones | 1 | 2021 | 47 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 309 | 0.040 |
Why?
|
| Nitriles | 1 | 2021 | 78 | 0.040 |
Why?
|
| Protein Binding | 2 | 2008 | 1076 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 171 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2002 | 128 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2020 | 12 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 169 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 160 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2020 | 18 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2000 | 24 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2000 | 25 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 534 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 289 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2000 | 74 | 0.040 |
Why?
|
| Capsid | 1 | 2000 | 64 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 95 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2002 | 429 | 0.040 |
Why?
|
| Acidosis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1341 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2000 | 196 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 680 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1574 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2019 | 574 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2013 | 268 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 50 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 711 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 230 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 122 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 64 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 128 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2598 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 670 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 188 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 366 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 233 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 198 | 0.020 |
Why?
|
| U937 Cells | 1 | 2011 | 30 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 49 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 297 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 279 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 203 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2005 | 722 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2009 | 50 | 0.020 |
Why?
|
| Genes, gag | 1 | 2008 | 5 | 0.020 |
Why?
|
| Leucine Zippers | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pancreas | 1 | 2007 | 45 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 933 | 0.020 |
Why?
|
| Reverse Transcription | 1 | 2007 | 23 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 148 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 8 | 0.020 |
Why?
|
| Gene Products, vpr | 1 | 2006 | 5 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 158 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 245 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 352 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 115 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 94 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 128 | 0.010 |
Why?
|
| Fusion Proteins, gag-pol | 1 | 2004 | 2 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 217 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 273 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 14 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1068 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 154 | 0.010 |
Why?
|
| Phylogeny | 1 | 2005 | 740 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 271 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 27 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2000 | 12 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 29 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2000 | 75 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 106 | 0.010 |
Why?
|
| Ovary | 1 | 2000 | 112 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 456 | 0.010 |
Why?
|